Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

Boehringer Ingelheim focuses on targeting the proteins involved in this process as a promising strategy for developing new cancer treatments. Credit: Tada Images/Shutterstock. Boehringer Ingelheim and ...

GoodRx announced a new partnership with Boehringer Ingelheim to provide discounts for a biosimilar to rheumatoid arthritis drug Humira Thursday, adding to an increasingly competitive market.

The drug was sold at different times by pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim. Lawsuits against the companies began piling up in both state and federal courts after ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

Forbes lists are exclusively determined by our editorial team. We do not accept payment for consideration or selection.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, ...